SML3038
JB170
≥98% (HPLC)
别名:
4-((9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-yl)amino)-N-(2-(2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetamido)ethoxy)ethoxy)ethyl)-2-methoxybenzamide, Thalidomide-PEG2-Alisertib
登录 查看组织和合同定价。
选择规格
变更视图
关于此项目
Assay:
≥98% (HPLC)
Form:
powder
Quality Segment
assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 2 mg/mL, clear (Warmed)
storage temp.
2-8°C
SMILES string
O=C1N(C2CCC(NC2=O)=O)C(C3=C1C(OCC(NCCOCCOCCNC(C4=CC=C(NC5=NC(C(C=CC(Cl)=C6)=C6C(C7=C(OC)C=CC=C7F)=NC8)=C8C=N5)C=C4OC)=O)=O)=CC=C3)=O
InChI key
GYKNPXCQINZRLL-UHFFFAOYSA-N
Biochem/physiol Actions
JB170 is a highly specific AURORA-A degrader (PROTAC) comprising aurora kinase inhibitor alisertib connected to the CEREBLON-binding molecule thalidomide. JB170 induces rapid and durable degradation of AURORA-A in cancer cells leading to strong S-phase arrest and apoptosis.
highly specific AURORA-A degrader (PROTAC) that induces rapid and durable degradation of AURORA-A in cancer cells
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable